The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways

被引:156
作者
Baudouin, Christophe [1 ,2 ,3 ]
Liang, Hong [3 ]
Hamard, Pascale [1 ,2 ]
Riancho, Luisa [4 ]
Creuzot-Garcher, Catherine [5 ]
Warnet, Jean-Michel [3 ,4 ]
Brignole-Baudouin, Francoise [3 ,4 ]
机构
[1] Quinze Vingts Natl Ophthalmol Hosp, Dept Ophthalmol, Versailles, France
[2] Univ Versailles, Ambroise Pare Hosp, APHP, Paris Ouest Sch Med, F-78000 Versailles, France
[3] Inst Biomed Cordeliers, INSERM, U598, Paris, France
[4] Univ Paris 05, Fac Biol & Pharmacol Sci, Dept Toxicol, Paris, France
[5] Burgundi Univ, Univ Hosp Dijon, Dept Ophthalmol, Sect Glaucoma, Dijon, France
关键词
D O I
10.1016/j.ophtha.2007.01.036
中图分类号
R77 [眼科学];
学科分类号
100212 [眼科学];
摘要
Purpose: To investigate the expression of CCR5 and CCR4, two chemokine receptors, as markers of the T helper (Th) 1 and Th2 pathways, respectively, and class 11 antigen HLA-DR as a hallmark of inflammation on conjunctival cells obtained from patients receiving long-term glaucoma treatment. Design: Case-control study. Participants: A total of 18 normal subjects and 70 glaucoma patients treated with topical antiglaucoma drugs for more than 1 year: 14 receiving a beta-blocker as monotherapy, 38 treated with a prostaglandin analog alone (19 with latanoprost, 6 with travoprost, 13 with bimatoprost), and 18 receiving multiple treatments. Methods: Impression cytologic specimens (ICSs) were obtained from 1 eye of the patients and processed for flow cytometry. Conjunctival cells were extracted and incubated with monoclonal antibodies against CCR4, CCR5, HLA-DR, or their specific controls to measure, in a masked manner, the percentages of conjunctival cells positive for the 3 markers. Main Outcome Measures: HLA-DR and chemokine receptors (CCR4 and CCR5) in ICSs. Results: Compared with all other groups, HLA-DR expression was raised significantly in the multitreatment group, whereas all monotherapies showed slight and nonsignificant increases. Both CCR4 and CCR5 were increased significantly in all 5 glaucoma groups compared with normal subjects, with no between-group differences. Conclusions: This study demonstrates the overexpression of 2 chemokine receptors in the conjunctival epithelium of glaucoma patients treated over the long term. These results show the simultaneous overexpression of CCR4 and CCR5, suggesting that the chronic use of topical treatments may stimulate both the Th1 and Th2 systems simultaneously. These results also suggest that inflammatory mechanisms combining allergy with toxicity are at work and illustrate the complexity of inflammatory reactions occurring in the ocular surface of glaucoma patients. Ophthalmology 2008; 115:109-115 (c) 2008 by the American Academy of Ophthalmology.
引用
收藏
页码:109 / 115
页数:7
相关论文
共 41 条
[1]
Abu El-Asrar AM, 2001, BRIT J OPHTHALMOL, V85, P1357
[2]
Ajjan RA, 1998, BRIT J RHEUMATOL, V37, P179
[3]
Annunziato F, 1998, EUR CYTOKINE NETW, V9, P12
[4]
CCR4 and CCR5 expression in conjunctival specimens as differential markers of TH1/TH2 in ocular surface disorders [J].
Baudouin, C ;
Liang, H ;
Bremond-Gignac, D ;
Hamard, P ;
Hreiche, R ;
Creuzot-Garcher, C ;
Warnet, JM ;
Brignole-Baudouin, F .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2005, 116 (03) :614-619
[5]
Ocular surface inflammatory changes induced by topical antiglaucoma drugs -: Human and animal studies [J].
Baudouin, C ;
Pisella, PJ ;
Fillacier, K ;
Goldschild, M ;
Becquet, F ;
De Saint Jean, M ;
Béchetoille, A .
OPHTHALMOLOGY, 1999, 106 (03) :556-563
[6]
Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term [J].
Baudouin, C ;
Hamard, P ;
Liang, H ;
Creuzot-Garcher, C ;
Bensoussan, L ;
Brignole, F .
OPHTHALMOLOGY, 2004, 111 (12) :2186-2192
[7]
Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s [J].
Bonecchi, R ;
Bianchi, G ;
Bordignon, PP ;
D'Ambrosio, D ;
Lang, R ;
Borsatti, A ;
Sozzani, S ;
Allavena, P ;
Gray, PA ;
Mantovani, A ;
Sinigaglia, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (01) :129-134
[8]
ADVERSE-EFFECTS OF TOPICAL ANTIGLAUCOMATOUS MEDICATIONS ON THE CONJUNCTIVA [J].
BRAODWAY, D ;
GRIERSON, I ;
HITCHINGS, R .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1993, 77 (09) :590-596
[9]
Brignole F, 2000, INVEST OPHTH VIS SCI, V41, P1356
[10]
Brignole F, 2001, INVEST OPHTH VIS SCI, V42, P90